In a recent study, onvansertib, when combined with the standard-of-care FOLFIRI and bevacizumab, was found to be well tolerated and showed a promising signal of efficacy in KRAS-mutated metastatic colorectal cancer patients [52], supporting the strategy of combining PLK1 inhibitors with approved therapies to enhance their effectiveness. The gene discussed is KRAS; the disease is metastatic colorectal cancer.